Recursion said it expects to launch its first registrational trial in the second half of 2027 for REC-4881, following positive oral familial adenomatous polyposis (FAP) data. The company’s plan is based on updated results from the Phase Ib/II TUPELO trial (NCT05552755), presented by Mayo Clinic’s Lisa Boardman, MD. Recursion reported that most patients treated with REC-4881 showed reductions in higher-risk polyp counts and lower GI polyp burden across the GI tract from a single oral therapy. The company said timing depends on continued talks with the FDA. The readout keeps attention on mechanism-driven, oral MEK1/MEK2 allosteric inhibition in a setting where patients face lifelong surveillance and surgery as standard care.